

Cancer is detected **too late**

10M


cancer deaths per year globally¹



1 in 5 diagnosed with cancer in their lifetime¹

Cancer is a thief. It robs us of our family members, of our comfort, of once-in-a-lifetime opportunities. But what if there were a way to reduce cancer deaths by half in the next 25 years?

This is the future Exact Sciences works toward every day. **Because we believe it's possible.**



We're changing lives, together

Exact Sciences is strategically positioned to support patients and providers.

4.6M
test results in 2024²

7,000+
global employees²

9
research and development centers and labs²

40+
global office locations

Our global team, advanced capabilities, infrastructure, and dedication to taking on the impossible fuel our mission.

We are continually innovating and combining scientific rigor with an open-minded approach to deliver the next big thing.

Supporting patients before, during and after diagnosis

Note: Tests in development are not available for commercial use. Availability of commercial tests outside of the US varies by country.

Am I at risk for cancer?

Hereditary Cancer Testing

Riskguard® A blood or saliva test that can uncover hereditary risk for certain cancers and help inform treatment decisions.

Might I have cancer?

Screening & Surveillance

Cologuard® A noninvasive stool test that screens for colon cancer and precancer in adults 45+ at average risk, Rx only.

Cologuard Plus™ Built on the success of the Cologuard test, Cologuard Plus screens for colon cancer and precancer in adults 45+ at average risk. The Cologuard Plus test uses biomarkers designed to deliver both high sensitivity and specificity. Rx only.

Oncoguard® Liver A blood test that helps find the most common liver cancer in people with cirrhosis and/or chronic hepatitis B.

Cancerguard™ A blood test designed to detect multiple cancers, even at early stages, to help expand the number of screened cancers.

**Multitarget
CRC Blood Test**
test in development A blood test designed to screen for colon cancer and provide people with an additional option to screen.

Will my patient benefit from radiation or chemotherapy?

Early-stage Treatment Guidance

Oncotype DX Breast Recurrence Score® A tumor-tissue early-stage breast cancer test that indicates risk of recurrence and possible chemotherapy benefit.

Oncotype DX Breast DCIS Score® A tumor-tissue early-stage DCIS breast cancer test that indicates risk of recurrence and possible radiation benefit.

Oncotype DX Colon Recurrence Score® A tumor-tissue colon cancer test that indicates risk of recurrence and possible chemotherapy benefit.

What is the best therapy for my cancer patient? Has my cancer returned?

Therapy Selection

OncoEXtra® A tumor normal, ultra comprehensive, tissue-based test that provides therapy selection guidance for advanced solid tumor cancers.

Oncoliquid™
test in development A blood (liquid biopsy) test being designed to provide therapy selection guidance for advanced cancer.

MRD & Recurrence Testing

Oncodetect™ A tumor-informed molecular residual disease test that helps guide therapy decisions, assess treatment response, and monitor for signs of cancer recurrence for patients with solid tumors.

Please visit the company's website [exactsciences.com](https://www.exactsciences.com) and follow Exact Sciences on X (formerly Twitter), Facebook and LinkedIn.

Sources

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
2. Internal Data on File. Exact Sciences Corporation. Madison, Wisconsin.

**EXACT
SCIENCES**®

Cologuard, Oncoguard, Riskguard, Cancerguard and Exact Sciences are trademarks of Exact Sciences Corporation.

Oncotype, Oncotype DX, OncoEXtra and Oncodetect are trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences Corporation. All other trademarks are the properties of their respective owners.

© 2025 Exact Sciences Corporation. All rights reserved. M-US-ES-00530.

